SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending due to a significant drop in share price after its NHS-Galleri cancer screening trial missed its primary endpoint for statistically significant reduction in late-stage diagnoses. The community is sharply divided, with some investors arguing it's an overreaction given strong cash reserves and positive U.S. sales, while others question the test's efficacy and commercial viability amid high cash burn.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following news of a royalty-based funding agreement, contingent on FDA approval for its lead prostate cancer candidate, alongside a proposed public stock offering. This dual financing is generating significant community discussion, with some investors concerned about potential dilution while others see it as a strategic move to secure capital for upcoming regulatory milestones and strengthen the company's commercialization position.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is seeing significant community discussion ahead of its NYSE Opening Bell ceremony, with many anticipating a short squeeze due to its small float and rising interest in the broader space sector. However, some investors are debating the company's long-term fundamentals and the direct impact of recent defense contract news.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending sharply lower after reporting an unexpected loss and weak forecast, driven by rising credit loss provisions, fueling intense debate among investors about the long-term viability of its "buy now, pay later" business model. Many express skepticism about consumer debt repayment, while others view the significant price drop as an overreaction and a buying opportunity for a major player in the fintech sector.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp's shares are actively discussed following its earnings report, where impressive beats on revenue and EPS were overshadowed by a weaker 2026 outlook for gold production and higher costs. This mixed news has sparked debate among traders, with some viewing the pullback as an overreaction and a buying opportunity given high gold prices, while others express concern over the company's future guidance.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending higher after its CAGNY conference presentation emphasized strong distribution and shelf space gains, fueling community discussion around accelerated growth and intensifying speculation of a potential PepsiCo acquisition.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending strongly ahead of its upcoming earnings report, driven by positive sentiment around robust performance in civil aerospace, expanding defense contracts, and significant growth opportunities in Small Modular Reactors and AI data center power. The community is actively discussing analyst upgrades, ongoing share buybacks, and the expectation of new all-time highs.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending after its Q4 earnings report, which, despite a revenue beat, showed a net loss and increased operating expenses as the company aggressively invests in growth. The community is actively discussing whether the resulting share price dip is an overreaction to strategic long-term spending, especially given the strong revenue outlook and extended patent protection for its key products.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending due to robust earnings that beat expectations and strong forward guidance, fueled by accelerating demand for optical components critical to AI data center infrastructure. The stock's parabolic surge is sparking intense debate, with many celebrating its powerful momentum and short squeeze potential, while others warn of extreme overvaluation and heavy insider selling.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending with high anticipation for its upcoming BLA resubmission for Deramiocel, a DMD treatment that showed robust Phase 3 efficacy, as the community discusses significant institutional interest, potential short squeeze dynamics, and hopes for accelerated FDA approval.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56%

Upstream Bio (NASDAQ:UPB) reported top-line results from its Phase II VALIANT trial evaluating verekitug in adults with severe asthma, highlighting statistically significant reductions in annualized...

Upstream Bio (NASDAQ:UPB) Sees Large Volume Increase - Here's Why

Upstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume - Here's What Happened...

Upstream Bio (NASDAQ:UPB) Trading Down 10.3% - Time to Sell?

Upstream Bio (NASDAQ:UPB) Trading Down 10.3% - Here's Why...

Upstream Bio (NASDAQ:UPB) Shares Gap Down - Here's Why

Upstream Bio (NASDAQ:UPB) Shares Gap Down - Should You Sell...

Biotech Stocks To Add to Your Watchlist - February 11th

Moderna, Danaher, Vertex Pharmaceuticals, Medpace, and Upstream Bio are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies...

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Upstream Bio shares rise after Phase 2 data show its asthma drug cut attacks by up to 56% and improved lung function. The company plans late-stage trials.read more...

<ul class="summary-bullets"><li>Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile.</li><li>Verekitug reduced asthma attacks by 56% with 100 mg, and 39% with 400 mg compared to placebo.</li><li>Upstream has begun planning Phase 3 studies.&nbsp;</li></ul>Shares of Upstream Bio Inc. (UPB) crashed more than 40% on Wednesday despite the company announcing positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.<h2 class="st-heading-2">Details Of The Test</h2>Verekitug, which targets the thymic stromal lymphopoietin (TSLP) receptor, reduced annual asthma attacks by 56% with 100 mg and 39% with 400 mg compared to placebo. Patients also showed improved lung function. Patients received Verekitug every 12 weeks for the 100 mg dose or every 24 weeks for the 400 mg dose.&nbsp;Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile. More than 90% of eligible participants have enrolled in the VALOUR long-term extension trial to further assess the treatment’s durability.“We intend to rapidly advance verekitug into Phase 3 trials in severe asthma and CRSwNP. In parallel, we also continue to progress verekitug in our ongoing Phase 2 VENTURE trial in patients with COPD, where we have enrolled more than 60% of patients to date,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio.&nbsp;<h2 class="st-heading-2">Phase 3 Studies Update</h2>Upstream Bio structured the VALIANT trial with endpoints intended to support potential approval filings, and has begun planning Phase 3 studies in severe asthma and CRSwNP, with registrational trials expected after regulatory discussions.The results reportedly aligned exactly with Amgen’s (AMGN) Tezspire in effectiveness. The drug requires 210 milligrams every four weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/UPB">UPB</a> on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said the market reaction was ‘unwarranted’.<stembedurl>https://stocktwits.com/stjernerogvann/message/644653420</stembedurl>Another user saw a buying opportunity.<stembedurl>https://stocktwits.com/lordBrian/message/644666591</stembedurl>Year-to-date, the stock has declined more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did UPB Stock Plunge 40% Today?

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

Equity

Upstream Bio (NASDAQ:UPB) Stock Price Up 9.4% - Here's What Happened

Upstream Bio (NASDAQ:UPB) Stock Price Up 9.4% - What's Next...

Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Rating of "Moderate Buy" from Analysts

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat Ratings...

Upstream Bio (NASDAQ:UPB) Stock Price Down 4.6% - Should You Sell?

Upstream Bio (NASDAQ:UPB) Trading Down 4.6% - Should You Sell...

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

UPB
Upstream Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UPB News

UPBUpstream Bio Inc.